1 May 2020 in Clinical Gastroenterology and Hepatology
We aimed to identify biomarkers that might be used to predict responses of patients with inflammatory bowel diseases (IBD) to vedolizumab therapy. We obtained biopsies from inflamed colon of patients with IBD who began treatment with vedolizumab (n = 31) or tumor necrosis factor (TNF) antagonists (n = 20) and performed RNA-sequencing analyses. We compared gene expression patterns between patients who did and did not enter endoscopic remission (absence of ulcerations at month 6 for patients with Crohn's disease or Mayo endoscopic subscore ≤1 at week 14 for patients with ulcerative colitis) and performed pathway analysis and cell deconvolution for training (n = 20) and validation (n = 11) datasets. Colon biopsies were also analyzed by immunohistochemistry. We validated a baseline gene expression pattern associated with endoscopic remission after vedolizumab therapy using 3 independent datasets (n = 66). We identified significant differences in expression levels of 44 genes between patients who entered remission after vedolizumab and those who did not; we found significant increases in leukocyte migration in colon tissues from patients who did not enter remission (P < .006). Deconvolution methods identified a significant enrichment of monocytes (P = .005), M1-macrophages (P = .05), and CD4+ T cells (P = .008) in colon tissues from patients who did not enter remission, whereas colon tissues from patients in remission had higher numbers of naïve B cells before treatment (P = .05). Baseline expression levels of PIWIL1, MAATS1, RGS13, and DCHS2 identified patients who did vs did not enter remission with 80% accuracy in the training set and 100% accuracy in validation dataset 1. We validated these findings in the 3 independent datasets by microarray, RNA sequencing and quantitative PCR analysis (P = .003). Expression levels of these 4 genes did not associate with response to anti-TNF agents. We confirmed the presence of proteins encoded by mRNAs using immunohistochemistry. We identified 4 genes whose baseline expression levels in colon tissues of patients with IBD associate with endoscopic remission after vedolizumab, but not anti-TNF, treatment. We validated this signature in 4 independent datasets and also at the protein level. Studies of these genes might provide insights into the mechanisms of action of vedolizumab.
23 December 2023 in Genes & Immunity
9 October 2026 in Research Square
Granulomas are a defining feature of Crohn’s disease associated with a more severe disease course, yet their developmental origins and cellular organization remain poorly understood. Here, we integrate single-cell and spatial transcriptomics of human intestinal tissues with in situ validation and functional macrophage assays to investigate granuloma formation. Crohn’s disease granulomas share cellular, transcriptional and spatial features with isolated lymphoid follicles, suggesting that chronic inflammation may repurpose pre-existing lymphoid structures. We identify a previously uncharacterized population of PLA2G2D-expressing macrophages enriched in isolated lymphoid follicles and at granuloma peripheries. Lymphotoxin-α1β2, LIGHT and TNF induce this macrophage programme in vitro , while TNF and low-dose lipopolysaccharide promote CXCL9 production together with PLA2G2D expression, potentially supporting effector T-cell recruitment in the granuloma environment. Conversely, SPP1-expressing macrophages preferentially occupy granuloma cores, are induced by IL-1β or hypoxia, and interact with inflammatory fibroblasts through profibrotic signalling networks. These findings define spatially and functionally distinct macrophage niches within Crohn’s disease granulomas and support a model in which inflammatory signals transform homeostatic lymphoid macrophage programmes to promote granuloma organization and fibrotic remodelling.